Raymond James analyst Gary Nachman downgraded INmune Bio (INMB) to Market Perform from Outperform.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- INmune Bio reports findings from Phase 2 MINDFuL trial of XPro
- Biotech INmune BIO (INMB) Collapses 60% after Alzheimer’s Trial Misses Goals
- INmune Bio reports primary endpoint of MINDFuL study not met
- INmune Bio down 52% after primary endpoint of MINDFuL study not met